Table 2.
Clinical data and laboratory tests in non-decreased and decreased group
| Characteristics | Non-decreased (n = 82) | Decreased (n = 45) | p value |
|---|---|---|---|
| Age | 53.68 ± 10.32 | 59.16 ± 11.87 | 0.008 |
| Sex | 0.098 | ||
| Male (%) | 70 (85.4) | 33 (73.3) | |
| Female (%) | 12 (14.6) | 12 (16.7) | |
| Etiology of cirrhosis | 0.745 | ||
| Alcoholics (%) | 48 (58.5) | 25 (55.6) | |
| Non-alcoholics (%) | 34 (41.5) | 20 (44.4) | |
| Reasons of use | 0.008 | ||
| Bleeding control (%) | 58 (70.7) | 41 (91.1) | |
| Hepatorenal syndrome (%) | 24 (29.3) | 4 (8.9) | |
| Infusion of albumin | 0.203 | ||
| Yes (%) | 33 (40.2) | 13 (28.9) | |
| No (%) | 49 (59.8) | 32 (71.1) | |
| Cumulative dose of Terlipressin (mg) | 15.38 ± 1.14 | 15.29 ± 4.08 | 0.914 |
| Amount of hydration (L) | 4.21 ± 1.99 | 4.70 ± 2.20 | 0.200 |
| Amount of sodium infused (mEq) | 313.14 ± 267.04 | 304.29 ± 320.97 | 0.864 |
| Total bilirubin (0 ~ 1.2 mg/dL) | 7.41 ± 9.72 | 3.33 ± 4.62 | 0.009 |
| Albumin (3.4 ~ 4.8 g/dL) | 2.61 ± 0.46 | 2.74 ± 0.54 | 0.164 |
| Creatinine (0.6 ~ 1.2 mg/dL) | 1.88 ± 1.75 | 1.20 ± 0.83 | 0.003 |
| Potassium (mmol/L) | 4.60 ± 1.03 | 4.33 ± 0.88 | 0.132 |
| Hemoglobin (13 ~ 17 g/dL) | 9.19 ± 2.47 | 9.06 ± 2.20 | 0.758 |
| *PT (0.8 ~ 1.2 *INR) | 1.83 ± 0.61 | 1.70 ± 0.62 | 0.253 |
| *MELD score | 21.07 ± 11.05 | 15.60 ± 9.52 | 0.004 |
| *MELD-Na | 25.95 ± 18.92 | 14.64 ± 11.46 | 0.000 |
| Child-Pugh score (6 ~ 18) | 9.24 ± 2.02 | 8.09 ± 2.64 | 0.013 |
| Initial sodium (135 ~ 145 mmol/L) | 131.96 ± 6.84 | 137.84 ± 3.56 | 0.000 |
| Lowest sodium (135 ~ 145 mmol/L) | 131.30 ± 6.58 | 128.73 ± 5.19 | 0.017 |
*PT, Prothrombin time; INR, International normalized ratio; MELD, Model for end-stage liver disease.